In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors and industry enthusiasts. In this article, we will perform an extensive industry comparison, evaluating UnitedHealth Group UNH in relation to its major competitors in the Health Care Providers & Services industry. By closely examining crucial financial metrics, market position, and growth prospects, we aim to offer valuable insights for investors and shed light on company's performance within the industry.
UnitedHealth Group Background
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the US as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
---|---|---|---|---|---|---|---|
UnitedHealth Group Inc | 36.71 | 5.39 | 1.36 | 4.65% | $7.67 | $21.06 | -0.94% |
Centene Corp | 12.80 | 1.28 | 0.23 | 4.41% | $1.96 | $4.64 | 3.9% |
Molina Healthcare Inc | 15.58 | 3.74 | 0.47 | 6.91% | $0.47 | $1.22 | 21.87% |
HealthEquity Inc | 85.64 | 3.27 | 6.61 | 1.39% | $0.08 | $0.19 | 17.66% |
Progyny Inc | 46.33 | 4.71 | 2.57 | 3.0% | $0.02 | $0.06 | 7.62% |
Average | 40.09 | 3.25 | 2.47 | 3.93% | $0.63 | $1.53 | 12.76% |
By analyzing UnitedHealth Group, we can infer the following trends:
-
With a Price to Earnings ratio of 36.71, which is 0.92x less than the industry average, the stock shows potential for growth at a reasonable price, making it an interesting consideration for market participants.
-
The elevated Price to Book ratio of 5.39 relative to the industry average by 1.66x suggests company might be overvalued based on its book value.
-
With a relatively low Price to Sales ratio of 1.36, which is 0.55x the industry average, the stock might be considered undervalued based on sales performance.
-
The Return on Equity (ROE) of 4.65% is 0.72% above the industry average, highlighting efficient use of equity to generate profits.
-
The company exhibits higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $7.67 Billion, which is 12.17x above the industry average, implying stronger profitability and robust cash flow generation.
-
The gross profit of $21.06 Billion is 13.76x above that of its industry, highlighting stronger profitability and higher earnings from its core operations.
-
The company is witnessing a substantial decline in revenue growth, with a rate of -0.94% compared to the industry average of 12.76%, which indicates a challenging sales environment.
Debt To Equity Ratio
The debt-to-equity (D/E) ratio is a key indicator of a company's financial health and its reliance on debt financing.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When comparing UnitedHealth Group with its top 4 peers based on the Debt-to-Equity ratio, the following insights can be observed:
-
UnitedHealth Group exhibits a relatively higher debt-to-equity ratio of 0.79 compared to its top 4 peers, suggesting a higher proportion of debt in the company's capital structure.
-
This higher level of debt can pose greater financial risk.
Key Takeaways
For UnitedHealth Group, the PE ratio is low compared to peers, indicating potential undervaluation. The high PB ratio suggests the market values the company's assets highly. A low PS ratio implies the stock price may not fully reflect revenue. The high ROE, EBITDA, and gross profit indicate strong profitability. However, the low revenue growth may raise concerns about future performance compared to industry peers in the Health Care Providers & Services sector.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.